USBC, Inc 8-K, filed Jul 27, 2021
USBC, Inc. (USBC)
8-K
2021-07-27
For: 2021-07-27
View Original
Added on
April 10, 2026
About this 8-K
USBC, Inc filed this 8-K on July 27, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): July 27,
2021
KNOW LABS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-30262
|
90-0273142
|
|
(State
of other jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
500 Union Street, Suite 810
Seattle, Washington 98101
(Address
of principal executive office)
(206) 903-1351
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company. ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other
Events.
On July 27, 2021, Know Labs, Inc. (the “Company”), an
emerging leader in non-invasive
medical diagnostics, announced that it had been granted the
following three patents:
–
U.S.
Patent No. 11,063,373: Non-invasive analyte sensor and system with
decoupled transmit and receive antennas
–
U.S.
Patent No. 11,031,970: Non-invasive analyte sensor and system with
decoupled and inefficient transmit and receive
antennas
–
U.S.
Patent No. 11,058,317:
Non-invasive detection of an analyte using decoupled and
inefficient transmit and receive antennas
The
patents were issued by the United
States Patent and Trademark Office. Each of the newly issued
patents relates to the unique configuration of the antennas used in
Know Labs’ Bio-RFID sensors. This unique arrangement enhances
Bio-RFID’s performance and improves its detection
capabilities in identifying and measuring a variety of analytes
non-invasively. The patents support the Company’s
medical diagnostic focus while also signaling potential for
additional non-medical applications. These new patents expand Know Labs’
intellectual property portfolio in radio frequency and microwave
spectroscopy, further improving its technological position as it
readies to launch non-invasive diagnostic
devices.
A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
Press
release dated July 27, 2021. Filed herewith.
|
-2-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Registrant:
KNOW LABS, INC.
By: /s/
Ronald P. Erickson
Ronald
P. Erickson
Chairman of the
Board
July
27, 2021
-3-
Exhibit
99.1
Three New Patents for Know Labs Expand IP Portfolio
and Signal Further Applications for Bio-RFIDTM
SEATTLE
– July 27, 2021 – Advancing the development of its
proprietary Bio-RFIDTM
platform technology while
continuing to deliver against its IP strategy, Know Labs, Inc.
(OTCQB:
KNWN) today announced it has been granted three new patents
that support its medical diagnostic focus while also signaling
potential for additional non-medical applications. These new patents expand Know Labs’
intellectual property portfolio in radio frequency and microwave
spectroscopy, further improving its technological position as it
readies to launch non-invasive diagnostic
devices.
“While we remain sharply focused on diagnostic medical device
applications for Bio-RFID, these new patents, combined with our
current portfolio, enhance Know Labs’ position beyond the
diagnostic realm and its potential for non-medical
applications,” said Phil Bosua, Bio-RFID inventor and Know
Labs CEO. “Our IP portfolio covers more than 100 different
analytes, which means Know Labs can offer valuable diagnostic
solutions beyond glucose monitoring devices.”
Each of the newly issued patents relates to the unique
configuration of the antennas used in Know Labs’ Bio-RFID
sensors. This unique arrangement enhances Bio-RFID’s
performance and improves its detection capabilities in identifying
and measuring a variety of analytes non-invasively. The specific
patents are:
–
U.S.
Patent No. 11,063,373: Non-invasive analyte sensor and system with
decoupled transmit and receive antennas
–
U.S.
Patent No. 11,031,970: Non-invasive analyte sensor and system with
decoupled and inefficient transmit and receive
antennas
–
U.S.
Patent No. 11,058,317:
Non-invasive detection of an analyte using decoupled and
inefficient transmit and receive antennas
“Our
primary focus is the development of our non-invasive glucose
monitoring device, and we continue to work toward FDA clinical
trials. However, Bio-RFID is a platform technology with a vast
number of potential applications that can add significant value to
multiple industries,” said Ron Erickson, Know Labs Founder
and Chairman. “It can be used for other medical applications,
such as validating the composition of drugs in ampoules or
measuring ketone levels in the body, and for non-medical
applications, such as detecting contaminants in food and drinks as
part of the quality control process. Our platform technology,
supported by our IP strategy, puts us in a great position to build
solutions for medical diagnostics and beyond.”
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under
the stock symbol “KNWN.” The Company’s technology
uses spectroscopy to
direct electromagnetic energy through a substance or material to
capture a unique molecular signature. The Company refers to its
technology as Bio-RFID™. The Bio-RFID technology can be
integrated into a variety of wearable, mobile, or bench-top form
factors. This patented and patent-pending technology makes it
possible to effectively conduct analyses that could only previously
be performed by invasive and/or expensive and time-consuming
lab-based tests. The first application of our Bio-RFID technology
will be in a product marketed as a glucose monitor. It will provide
the user with real-time information on their blood glucose levels.
This product will require U.S. Food and Drug Administration
approval prior to its introduction to the market.
Safe Harbor Statement
This
release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,”
“should,” “would,” “plans,”
“expects,” “anticipates,”
“continue,” “estimate,”
“project,” “intend,” “likely,”
“forecast,” “probable,”
“potential,” and similar expressions and variations
thereof are intended to identify forward-looking statements.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, many of which are beyond Know Labs, Inc.’s
ability to control, and actual results may differ materially from
those projected in the forward-looking statements as a result of
various factors. These risks and uncertainties also include such
additional risk factors as are discussed in the Company’s
filings with the U.S. Securities and Exchange Commission, including
its Annual Report on Form 10-K for the fiscal year ended September
30, 2020, Forms 10-Q and 8-K, and in other filings we make with the
Securities and Exchange Commission from time to time. These
documents are available on the SEC Filings section of the Investor
Relations section of our website at www.knowlabs.co.
The Company cautions readers not to place undue reliance upon any
such forward-looking statements, which speak only as of the date
made. The Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made.
Know Labs, Inc. Contact:
Jordyn
(Theisen) Hujar
jordyn@knowlabs.co
Ph.
(206) 629-6414